Aquestive Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

Aquestive Therapeutics

03/03/2023 23:57

* Aquestive Therapeutics Inc  AQST.OQ   AQST.O  is expected
to show a fall in quarterly revenue when it reports  results on
March 7. 
    * The Warren New Jersey-based  company is expected to report
 a
6.0% decrease in revenue to $10.417 million from $11.08 million
a year ago, according to the mean estimate from 7 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Aquestive
Therapeutics
Inc is for a loss of 23 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aquestive
Therapeutics Inc is $5​, above​ its last closing price of $0.79.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.31       -0.31      -0.23     Beat    26.3
 Jun. 30 2022  -0.36       -0.36      -0.36     Met     0
 Mar. 31 2022  -0.39       -0.41      -0.32     Beat    21.6​
 Dec. 31 2021  -0.42       -0.47      -0.38     Beat    18.7
 ​​Sep.        -0.43       -0.45      -0.37     Beat    17.8
 30 2021                                                
 Jun. 30 2021  -0.44       -0.44      -0.33     Beat    24.7​
 Mar. 31 2021  -0.43       -0.43      -0.41     Beat    3.8
 Dec. 31 2020  -0.49       -0.26      -0.60     Missed  -130.8
 This summary was machine generated March 3 at 23:57 GMT.  All
figures in US dollars  unless otherwise stated